DOI: http://dx.doi.org/10.18203/2349-3933.ijam20194142

Anemia and inflammation, a link between end stage kidney disease and left ventricular hypertrophy

T. Madhusudhana Rao, B. H. V. K. Praveen Varma, D. S. S. K. Raju

Abstract


Background: Based on Glomerular Filtration Rate (GFR) Chronic Kidney Disease patients are classified into five stages. It starts with early stage of CKD and finally ends with End Stage Kidney Disease (ESKD). Anemia and inflammation are major medical complication in End Stage Kidney Disease and leads cardio vascular complications like LVH.

Methods: A cross sectional study carried out over a 2 year period in Department Nephrology and General Medicine OPD, MIMS, Vizianagaram, Andhra Pradesh, India 120 in which 60 are normal healthy individuals and 60 are End stage kidney Disease. In all the participants Serum creatinine, blood urea, Serum Iron, TIBC, TSAT% Serum ferritin, Serum CRP, IL-6 and TNF-α was measured. All the EDTA blood samples were analyzed for complete blood count. 

Results: The diagnostic criteria for CKD like blood urea and serum creatinine were significantly higher in ESKD. There is a significantly increased level of Left ventricular mass index in ESKD when compared with Control. The mean erythrocyte indices are decreased in ESKD. The mean serum iron, TIBC and TSAT% decreased ESKD. Whereas serum ferritin significant increase in ESKD group and the mean serum CRP IL-6 and TNF-α significant increase in ESKD group when compared with control

Conclusion: Present study finding suggested that there is a raised inflammatory marker in ESKD patients due to inflammation and it further changes serum ferritin, serum iron and TIBC. The above altered factors leads to changes in erythrocyte indices and leads to anemia which ends with cardiovascular complication like Left Ventricular Hypertrophy.


Keywords


Anemia, End stage kidney disease, Inflammation, Left ventricular hypertrophy

Full Text:

PDF

References


Gooneratne IK, Ranaweera AK, Liyanarachchi NP, Gunawardane N, Lanerolle RD. Epidemiology of chronic kidney disease in a Sri Lankan population. International journal of diabetes in developing countries. 2008 Apr;28(2):60.

Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. The Lancet. 2008 Jun 28;371(9631):2173-82.

Weiner DE, Tighiouart H, Vlagopoulos PT. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2005;16:1803-10.

Fehally J, Floege J, Johnson R. Comprehensive clinical nephrology Philadelphia. Elsevier. 2003;1:853-60.

Koch KM, Patyna D, Shaldon S, Werner E. Anemia of the regular hemodialysis patient and its treatment. Nephron. 1974;12(5):405-19.

Geerlings W, Morris RW, Brunner FP. Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA registry. Nephrol Dial. Transplant. 1993;8(7):585-9.

Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997;29(3):319-33.

Laura SH, Hal EB, Scott C, et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from fac mice. Blood. 1998;91(1):4092-98.

Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin A potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4(6):1051-6.

Merino A, Nogueras S, Buendía P, Ojeda R, Carracedo J, Ramirez-Chamond R, et al. Microinflammation and endothelial damage in hemodialysis. In Hemodialysis-From Basic Research to Clinical Trials. 2008;161:83-8.

Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Society Nephrol. 2004 Dec 1;15(12):3184-91.

Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Society of Nephrol. 2005 Jun 1;16(6):1803-10.

Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. J Am Coll Cardiol. 1995;25(4):879-84.

Tiffany TO, Jansen JM, Burtis CA, Overton JB, Scott CD. Enzymatic kinetic rate and end-point analyses of substrate, by use of a GeMSAEC fast analyzer. Clin Chem. 1972;18(8):829-40.

Bowers LD. Kinetic serum creatinine assays I. The role of various factors in determining specificity. Clin Chem. 1980;26(5):551-4.

Raju DSSK, Lalitha DL, Kiranmayi P. Observation of estimated GFR in the assessment of chronic kidney disease: application and practice. Asian J Pharm Clin Res. 2012;5(4):201-6.

Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferro zine reagent without deproteinization. Clin. Chem. 1984;30(6):975.

Rangel ÉB, Andreoli MC, Matos AC, Guimaraes-Souza NK, Mallet AC, et al. Hemoglobin and hematocrit at the end of hemodialysis: a better way to adjust erythropoietin dose?. J Artificial Organs. 2010;13(1):63-6.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. science. 2004 Dec 17;306(5704):2090-3.

Miura Y. Serum transferrin levels in chronic renal failure. II. The relationship between anemia and nutrition in regular hemodialysis patients (author's transl). Nihon Jinzo Gakkai Shi. 1978 Mar;20(3):243.

Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?. Clinical Journal of the American Society of Nephrology. 2006 Sep 1;1(1):S9-18.

Charytan C, Qunibi W, Bailie GR. Comparison of intravenous Fe sucrose to oral Fe in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. Clin. Pract. 2005;100(3):55-62.

Parkkinen J, Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol. Dial. Transplant. 2000;15(11):1827-34.

Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunderplassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J. Am. Soc. Nephrol. 2003;14(10):2639-44.

Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int. Urol. Nephrol. 2003;35(3):393-7.